Celsion CorpChange company Symbol lookupSelect an option...CLSN Celsion CorpCPFXF Copper Fox Metals IncDDAIF Daimler AGREI Ring Energy IncCZSVF Goldcore Resources LtdAAPL Apple IncPMBC Pacific Mercantile BancorpMSFT Microsoft CorpO Realty Income CorpCRLBF Cresco Labs IncGo
Change company Symbol lookup
Select an option...
CLSN Celsion Corp
CPFXF Copper Fox Metals Inc
DDAIF Daimler AG
REI Ring Energy Inc
CZSVF Goldcore Resources Ltd
AAPL Apple Inc
PMBC Pacific Mercantile Bancorp
MSFT Microsoft Corp
O Realty Income Corp
CRLBF Cresco Labs Inc
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Small Cap Value
Company profileCelsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
|
|
|
|
| |
| Annual Earnings Beat Consensus (Year ending 12/2019) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Annual Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced March 25, 2020 | -$0.77 | Annual Consensus of 3 analysts | -$0.87 | Difference from consensus | 12.60% | 2020 Earnings will announce | (Unconfirmed) March 24, 2021 |
Annual Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
CLSN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.